Market Access Granted in France for Aggressive non-Hodgkin Lymphoma ... The Herald | HeraldOnline.com The European Medicines Agency's (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who ... CELL THERAPEUTICS INC : Market Access Granted in France for Aggressive ... |
